Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors from the central anxious process, conolidine modulates alternate molecular targets. A Science Advancements review found that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://davido864lmn4.mdkblog.com/profile